Pharma4Future
Pharma4Future is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2024 annual accounts show equity of €317k and a net result of €130k. Equity is growing by ~63.2% per year across the filed fiscal years. Its solvency ranks better than 14% of 1393 sector peers (fiscal year 2024). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €317k |
| Net result | €130k |
| Better than sector | 14% |
| Active | 4 yrs |
Mixed profile: strong on profitability, weaker on health.
This is a financial institution (bank, insurer or financial holding). Our bankruptcy model is trained on ordinary trading and manufacturing companies; a bank balance sheet falls outside that scope. We therefore show no bankruptcy probability rather than a misleading figure.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 6.3% | 37.1% | |
| Net result | €130k | €46k | |
| Equity | €317k | €362k | |
| Gross operating margin | €260k | €66k | |
| Employees (FTE) | 0.0 | 0.0 |
| Fiscal year | 2024 |
|---|---|
| Revenue | n/a |
| EBITDA | n/a |
| Net profit | €130k |
| Cash flow | n/a |
| Staff costs | - |
| Income taxes | €43k |
| Dividends | - |
| Total assets | €5.02M |
| Equity | €317k |
| Debt | €4.70M |
| of which ≤ 1y | €1.06M |
| of which > 1y | €3.64M |
| Working capital | n/a |
| Employees (FTE) | 0.0 |
| 2024 | |
|---|---|
| Current ratio | n/a |
| Quick ratio | n/a |
| Working capital ratio | n/a |
| Solvency | 6.3% |
| Debt / equity | n/a |
| Long-term debt ratio | n/a |
| Interest coverage | n/a |
| Gross margin | n/a |
| Net margin | n/a |
| ROA | 2.6% |
| ROE | 40.9% |
| EBITDA margin | n/a |
| Days sales outstanding | n/a |
| Days payable outstanding | n/a |
| Inventory turnover | n/a |
| Days inventory (DSI) | n/a |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €5.02M |
| Fixed assets | 21/28 | €4.99M |
| Tangible fixed assets | 22/27 | €616k |
| Financial fixed assets | 28 | €4.37M |
| Current assets | 29/58 | €32k |
| Amounts receivable within one year | 40/41 | €7k |
| Cash & bank | 54/58 | €25k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €5.02M |
| Equity | 10/15 | €317k |
| Contributions / capital | 10/11 | €10k |
| Reserves | 13 | €307k |
| Amounts payable | 17/49 | €4.70M |
| Amounts payable after one year | 17 | €3.64M |
| Amounts payable within one year | 42/48 | €1.06M |
| Trade debts payable within one year | 44 | €3k |
| Income statement | ||
| Gross operating margin | 9900 | €260k |
| Operating result | 9901 | €233k |
| Financial charges | 65 | €60k |
| Result before taxes | 9903 | €173k |
| Income taxes | 67/77 | €43k |
| Net result for the period | 9904 | €130k |
| Result to be appropriated | 9905 | €130k |
| NACE primary | Financial services(64210) |
| Legal form | Private limited company(610) |
| Incorporation | 22-10-2021 |
| Status | Active |
| Postal code | 1745 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 23060B0465/00W000 | Flanders | 1,897 m² | 1 · 156 m² | 12.1 m · 3 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
02-04-2026 Act object · General meeting · Officer removal death · Officer discharge
- Publication: 2026-04-02 · Pharma4Future
- Filing: 2026-03-26 · Pharma4Future
- Act object: Kennisname van het ontslag van een bestuurder · Pharma4Future
- General meeting: date: 2026-03-12, type: bijzondere algemene vergadering · Pharma4Future
- Officer removal death: date: 2026-03-12, reason: ontslag · Elpers Farma BV
- Officer discharge: date: 2026-03-12 · Elpers Farma BV
- Power of attorney: date: 2026-03-12, scope: alle vereiste formaliteiten te vervullen en om alle noodzakelijke stappen te nemen m.b.t. de beslissing op heden genomen door de bijzondere algemene vergadering, met het oog op de neerlegging en bekendmaking ervan en namens de Vennootschap daartoe alle noodzakelijke documenten te ondertekenen · Wim Vandenberghe
- Power of attorney: date: 2026-03-12, scope: alle vereiste formaliteiten te vervullen en om alle noodzakelijke stappen te nemen m.b.t. de beslissing op heden genomen door de bijzondere algemene vergadering, met het oog op de neerlegging en bekendmaking ervan en namens de Vennootschap daartoe alle noodzakelijke documenten te ondertekenen · Ho Nam Lo
Technical details
{
"facts": [
{
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 02/04/2026",
"value": "2026-04-02",
"object": null,
"subject": "e1"
},
{
"type": "filing",
"quote": "neergelegd/ontvangen op 26 MART 2026 ter griffie van de Nederlandstalige ondernemingsrechtbank Brussel",
"value": "2026-03-26",
"object": null,
"subject": "e1"
},
{
"type": "act_object",
"quote": "Onderwerp akte: Kennisname van het ontslag van een bestuurder",
"value": "Kennisname van het ontslag van een bestuurder",
"object": null,
"subject": "e1"
},
{
"type": "general_meeting",
"quote": "Uittreksel uit de notulen van de bijzondere algemene vergadering van de besloten vennootschap Pharma4Future gehouden op 12 maart 2026",
"value": {
"date": "2026-03-12",
"type": "bijzondere algemene vergadering"
},
"object": null,
"subject": "e1"
},
{
"type": "officer_removal_death",
"quote": "Vervolgens neemt de vergadering met drie vierde van de stemmen beslissing om over te gaan tot ontslag van de bestuurder Elpers Farma BV en dit vanaf heden.",
"value": {
"date": "2026-03-12",
"reason": "ontslag"
},
"object": "e1",
"subject": "e2"
},
{
"type": "officer_discharge",
"quote": "De vergadering verleent geen tussentijdse kwijting aan de ontslagnemende bestuurder voor de normale uitoefening van zijn mandaat tot en met heden.",
"value": {
"date": "2026-03-12",
"granted": false
},
"object": "e1",
"subject": "e2"
},
{
"type": "power_of_attorney",
"quote": "De vergadering verleent volmacht aan de heer Wim Vandenberghe en de heer Ho Nam Lo, advocaten kantoor houdende te 9000 Gent. Vrijheidslaan 27, elk van hen alleen handelend en met recht van indeplaatsstelling, om alle vereiste formaliteiten te vervullen en om alle noodzakelijke stappen te nemen m.b.t. de beslissing op heden genomen door de bijzondere algemene vergadering, met het oog op de neerlegging en bekendmaking ervan en namens de Vennootschap daartoe alle noodzakelijke documenten te ondertekenen.",
"value": {
"date": "2026-03-12",
"scope": "alle vereiste formaliteiten te vervullen en om alle noodzakelijke stappen te nemen m.b.t. de beslissing op heden genomen door de bijzondere algemene vergadering, met het oog op de neerlegging en bekendmaking ervan en namens de Vennootschap daartoe alle noodzakelijke documenten te ondertekenen",
"substitution": true
},
"object": "e1",
"subject": "e7"
},
{
"type": "power_of_attorney",
"quote": "De vergadering verleent volmacht aan de heer Wim Vandenberghe en de heer Ho Nam Lo, advocaten kantoor houdende te 9000 Gent. Vrijheidslaan 27, elk van hen alleen handelend en met recht van indeplaatsstelling, om alle vereiste formaliteiten te vervullen en om alle noodzakelijke stappen te nemen m.b.t. de beslissing op heden genomen door de bijzondere algemene vergadering, met het oog op de neerlegging en bekendmaking ervan en namens de Vennootschap daartoe alle noodzakelijke documenten te ondertekenen.",
"value": {
"date": "2026-03-12",
"scope": "alle vereiste formaliteiten te vervullen en om alle noodzakelijke stappen te nemen m.b.t. de beslissing op heden genomen door de bijzondere algemene vergadering, met het oog op de neerlegging en bekendmaking ervan en namens de Vennootschap daartoe alle noodzakelijke documenten te ondertekenen",
"substitution": true
},
"object": "e1",
"subject": "e8"
}
],
"act_meta": {
"model_id": 40,
"extractor": "open-capture-27b-v3",
"ocr_chars": 2445,
"truncated": false,
"needs_verify": false
},
"entities": [
{
"id": "e1",
"kbo": "0776.403.737",
"kind": "company",
"name": "Pharma4Future",
"attrs": {
"seat": "1745 Opwijk, Heiveld 29 bus 101",
"legal_form": "besloten vennootschap"
}
},
{
"id": "e2",
"kbo": "0538.703.158",
"kind": "company",
"name": "Elpers Farma BV",
"attrs": {
"seat": "1700 Dilbeek, Stationsstraat 253"
}
},
{
"id": "e3",
"kbo": null,
"kind": "person",
"name": "Thomas Elpers",
"attrs": {
"role": "permanent_representative"
}
},
{
"id": "e4",
"kbo": null,
"kind": "company",
"name": "Tournov BV",
"attrs": {}
},
{
"id": "e5",
"kbo": null,
"kind": "company",
"name": "The Wall Company",
"attrs": {}
},
{
"id": "e6",
"kbo": null,
"kind": "company",
"name": "Pharma Officinalis",
"attrs": {}
},
{
"id": "e7",
"kbo": null,
"kind": "person",
"name": "Wim Vandenberghe",
"attrs": {
"role": "attorney"
}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "Ho Nam Lo",
"attrs": {
"role": "attorney"
}
}
]
}26-10-2021 Incorporation of a new BV
Technical details
{
"kind": "oprichting",
"seat": "1745 Opwijk, Heiveld 29 bus 101",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": {
"kbo": "0819.551.515",
"name": "TOURNOV"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "Ordinary",
"partner_role": null,
"holder_org_kbo": "0819.551.515",
"holder_org_name": "TOURNOV",
"contribution_type": "cash",
"amount_paid_in_eur": 2500,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 750,
"amount_subscribed_eur": 2500,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": "0538.703.158",
"name": "Elpers Farma"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "Ordinary",
"partner_role": null,
"holder_org_kbo": "0538.703.158",
"holder_org_name": "Elpers Farma",
"contribution_type": "cash",
"amount_paid_in_eur": 2500,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 750,
"amount_subscribed_eur": 2500,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": "0474.385.428",
"name": "THE WALL COMPANY"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "Ordinary",
"partner_role": null,
"holder_org_kbo": "0474.385.428",
"holder_org_name": "THE WALL COMPANY",
"contribution_type": "cash",
"amount_paid_in_eur": 2500,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 750,
"amount_subscribed_eur": 2500,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": "0842.146.872",
"name": "Pharma Officinalis"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "Ordinary",
"partner_role": null,
"holder_org_kbo": "0842.146.872",
"holder_org_name": "Pharma Officinalis",
"contribution_type": "cash",
"amount_paid_in_eur": 2500,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 750,
"amount_subscribed_eur": 2500,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 10000,
"subject_company": {
"kbo": "0776.403.737",
"name_full": "Pharma4Future",
"legal_form": "BV"
},
"initial_directors": [],
"incorporation_date": "2021-10-19",
"post_incorporation_mandates": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | Pharma4Future |